Growing healthcare and research sectors drive need for molecular diagnostics and testing technologies
Global provider of sample and assay technologies QIAGEN has formed an Indian subsidiary, QIAGEN India Pvt Ltd, in New Delhi to begin direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.
QIAGEN has been active in India since 1995 and has developed numerous initiatives, partnerships and a strong network, and the new office is a further milestone in the company’s strategy to expand its footprint in emerging, high-growth regions. The New Delhi office is expected to grow to a staff of more than 30 in 2011.
India's domestic in vitro diagnostics market is projected to grow at 15% annually in the next few years and to accelerate going forward due to government incentive programmes and infrastructure investment.
‘India is a strategic market for the global expansion of QIAGEN, with 1.2 billion people and rapidly growing healthcare and r&d sectors,’ said Peer Schatz, ceo of QIAGEN.
‘The great potential for our molecular diagnostic technologies to serve patients in India, along with the research needs of the country's robust pharmaceutical segment, emerging applied testing market and a rapidly increasing academic market, make India a perfect fit for our growth and geographic expansion goals.’
QIAGEN says its diverse product portfolio is well suited to serve India's unique healthcare needs, as well as to advance pharmaceutical r&d in India.